Malabsorption-associated warfarin resistance

被引:13
作者
Sabol, Brian J. [1 ]
Basa, Ramon R. [2 ,3 ]
Wilkins, Charles E. [3 ,4 ]
机构
[1] St Claire Hosp, Dept Clin Pharm, Lakewood, CO USA
[2] St Claire Hosp, Franciscan Med Grp, Lakewood, CO USA
[3] St Elizabeth Hlth Ctr, Dept Internal Med, Youngstown, OH USA
[4] Northeastern Ohio Univ Coll Med & Pharm, Coll Med, Dept Internal Med, Rootstown, OH 44272 USA
关键词
Absorption; Albuterol; Anticoagulants; Aspirin; Atorvastatin calcium; Diazepam; Dosage; Fluticasone; International normalized ratio; Metoprolol tartrate; Salmeterol; Venous thrombosis; Warfarin sodium; SHORT-BOWEL SYNDROME; COUMARIN ANTICOAGULANT DRUGS; HEREDITARY RESISTANCE; ABSORPTION; PATIENT; RISK; PHARMACODYNAMICS; GENOTYPE; 5-MG;
D O I
10.2146/ajhp080477
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose. A case of malabsorption-associated warfarin resistance is reported. Summary. A 42-year-old, 111-kg, Caucasian man arrived at the emergency department with atypical pleuritic chest pain. The chest pain was associated with shortness of breath, diaphoresis, nausea, vomiting, and tachycardia. The patient's medical history was significant for multiple episodes of deep venous thrombosis (DVT) in the left upper extremity and both lower extremities, a right above-the-knee amputation due to complications of a previous DVT, insertion of a vena cava filter, pulmonary embolism (PE), asthma, hypertension, and multiple myocardial infarctions. During admission, he was diagnosed presumptively with PE. All potential causes of interference with warfarin absorption were investigated and ruled out. IN. warfarin therapy at a conventional initial dosage of 5 mg once daily was started on hospital day 2. The International Normalized Ratio (INR) reached the therapeutic range after increasing the i.v. warfarin dosage to 7.5 mg once daily on hospital day 6. The ability to obtain a therapeutic INR on a relatively low dosage of i.v. warfarin but not high dosages of oral warfarin strongly suggests an inherent warfarin malabsorption defect in this patient. Conclusion. A 42-year-old man with a history of recurrent thromboembolisms demonstrated resistance to oral warfarin therapy due to warfarin malabsorption.
引用
收藏
页码:1548 / 1553
页数:6
相关论文
共 31 条
[1]   Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications [J].
Aithal, GP ;
Day, CP ;
Kesteven, PJL ;
Daly, AK .
LANCET, 1999, 353 (9154) :717-719
[2]   HEREDITARY WARFARIN RESISTANCE - INVESTIGATION OF A RARE PHENOMENON [J].
ALVING, BM ;
STRICKLER, MP ;
KNIGHT, RD ;
BARR, CF ;
BERENBERG, JL ;
PECK, CC .
ARCHIVES OF INTERNAL MEDICINE, 1985, 145 (03) :499-501
[3]   Pharmacology and management of the vitamin K antagonists [J].
Ansell, Jack ;
Hirsh, Jack ;
Hylek, Elaine ;
Jacobson, Alan ;
Crowther, Mark ;
Palareti, Gualtiero .
CHEST, 2008, 133 (06) :160S-198S
[4]  
BRECKENRIDGE A, 1974, CLIN PHARMACOL THER, V15, P424
[5]  
BRECKENRIDGE A, 1973, CLIN PHARMACOL THER, V14, P955
[6]  
Brophy DF, 1998, PHARMACOTHERAPY, V18, P646
[7]   A randomized trial comparing 5-mg and 10-mg warfarin loading doses [J].
Crowther, MA ;
Ginsberg, JB ;
Kearon, C ;
Harrison, L ;
Johnson, J ;
Massicotte, P ;
Hirsh, J .
ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (01) :46-48
[8]  
FREMONT R, 1957, JAMA-J AM MED ASSOC, V165, P1382
[9]  
Gardemann A, 1999, THROMB HAEMOSTASIS, V82, P1121
[10]   Intravenous warfarin as an alternative for anticoagulation [J].
Gellatly, Rochelle M. .
PHARMACOTHERAPY, 2007, 27 (06) :933-935